Prostate cancer · Oligometastatic mCRPC · SBRT+enzalutamide
GROUQ-PCS 9
Does SBRT added to ADT+enzalutamide improve radiographic PFS in oligometastatic mCRPC?
Randomized phase II; 102 randomized, 100 analyzed; ≤5 metastases. ADT+enzalutamide vs same+SBRT.
Trial design
Randomized phase II; 102 randomized, 100 analyzed; ≤5 metastases. ADT+enzalutamide vs same+SBRT.
Outcome visualization · source-reported data
Median radiographic PFS
HR 0.48 (95% CI 0.27–0.86); p=0.014
Visualization reflects reported outcomes; it does not itself generate an NNT or establish an overall-survival benefit.
Key result
Median radiographic PFS was 4.6 vs 2.3 years. Phase II scale and selection limit generalization.
Interpretation and limitations
https://pubmed.ncbi.nlm.nih.gov/40907514/
Primary source
undefined
Read source →